Madrigal Pharmaceuticals Inc (MDGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) has a cash flow conversion efficiency ratio of -0.221x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-133.46 Million) by net assets ($602.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Madrigal Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Madrigal Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Madrigal Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Madrigal Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Madrigal Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Madrigal Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Penske Automotive Group Inc
NYSE:PAG
|
0.038x |
|
PayPay Corporation American Depository Shares
NASDAQ:PAYP
|
-0.121x |
|
Shanghai Electric Group Co Ltd
SHG:601727
|
0.009x |
|
VERBUND AG
VI:VER
|
0.039x |
|
Eiffage SA
PA:FGR
|
0.054x |
|
Aker ASA
OL:AKER
|
0.059x |
|
Equity Lifestyle Properties Inc
NYSE:ELS
|
0.107x |
|
Doosan Corp.
KO:000150
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Madrigal Pharmaceuticals Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Madrigal Pharmaceuticals Inc from 2003 to 2025. View Madrigal Pharmaceuticals Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $602.69 Million | $-189.55 Million | -0.315x | +47.92% |
| 2024-12-31 | $754.38 Million | $-455.57 Million | -0.604x | +24.50% |
| 2023-12-31 | $405.33 Million | $-324.23 Million | -0.800x | +29.78% |
| 2022-12-31 | $197.39 Million | $-224.86 Million | -1.139x | -21.47% |
| 2021-12-31 | $196.11 Million | $-183.92 Million | -0.938x | -42.84% |
| 2020-12-31 | $239.97 Million | $-157.56 Million | -0.657x | -557.10% |
| 2019-12-31 | $416.56 Million | $-41.62 Million | -0.100x | -86.86% |
| 2018-12-31 | $476.98 Million | $-25.51 Million | -0.053x | +56.33% |
| 2017-12-31 | $182.26 Million | $-22.32 Million | -0.122x | +74.68% |
| 2016-12-31 | $36.41 Million | $-17.61 Million | -0.484x | +65.88% |
| 2015-12-31 | $50.41 Million | $-71.44 Million | -1.417x | -16.97% |
| 2014-12-31 | $65.14 Million | $-78.92 Million | -1.212x | +23.16% |
| 2013-12-31 | $49.09 Million | $-77.41 Million | -1.577x | -118.66% |
| 2012-12-31 | $75.07 Million | $-54.13 Million | -0.721x | +77.47% |
| 2011-12-31 | $14.77 Million | $-47.30 Million | -3.202x | -96.78% |
| 2010-12-31 | $23.48 Million | $-38.20 Million | -1.627x | -51.17% |
| 2009-12-31 | $24.91 Million | $-26.81 Million | -1.076x | -266.77% |
| 2008-12-31 | $-58.79 Million | $-37.94 Million | 0.645x | -40.98% |
| 2007-12-31 | $24.90 Million | $27.22 Million | 1.093x | -96.39% |
| 2006-12-31 | $-1.75 Million | $-52.98 Million | 30.329x | +2671.96% |
| 2005-12-31 | $52.48 Million | $-61.88 Million | -1.179x | -311.59% |
| 2004-12-31 | $117.96 Million | $-33.80 Million | -0.287x | +6.70% |
| 2003-12-31 | $76.89 Million | $-23.61 Million | -0.307x | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.